导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.87% | 260/344 |
| 近一周 | -3.24% | 221/350 |
| 近一月 | -6.81% | 264/350 |
| 近一季 | -10.25% | 307/350 |
| 近半年 | -5.60% | 237/346 |
| 近一年 | -15.02% | 212/339 |
| 近两年 | 2.12% | 280/304 |
| 近三年 | -3.65% | 213/240 |
| 成立以来 | 191.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.24% 280/360 |
3.31% 169/366 |
- - |
- - |
| 2025 | 11.99% 267/358 |
-6.03% 234/340 |
10.92% 124/348 |
6.89% 247/354 |
0.52% 158/358 |
| 2024 | 4.68% 214/329 |
7.66% 83/280 |
-7.87% 276/310 |
3.11% 199/318 |
2.36% 122/329 |
| 2023 | 10.63% 83/275 |
16.86% 40/205 |
6.51% 87/230 |
-16.64% 229/262 |
6.61% 131/276 |
| 2022 | -14.94% 67/201 |
-9.74% 93/153 |
-14.60% 114/164 |
2.16% 18/189 |
8.01% 116/202 |
| 2021 | 15.98% 50/150 |
2.82% 110/312 |
7.90% 94/328 |
-6.76% 195/358 |
12.12% 14/151 |
| 2020 | 23.57% 26/103 |
-20.46% 215/280 |
20.91% 93/295 |
10.88% 43/299 |
15.87% 46/305 |
| 2019 | 27.72% 26/88 |
10.81% 108/258 |
5.29% 33/268 |
-0.68% 166/253 |
10.22% 73/266 |
| 2018 | -9.00% 45/79 |
- - |
- - |
- - |
-15.00% 170/241 |
| 2017 | 26.67% 16/69 |
- - |
- - |
- - |
- - |
| 2016 | 3.72% 32/59 |
- - |
- - |
- - |
- - |
| 2015 | 0.66% 21/49 |
- - |
- - |
- - |
- - |
| 2014 | -3.82% 79/99 |
- - |
- - |
- - |
- - |
| 2013 | 31.51% 3/70 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 易方达标普消费品指数A VS. 建信富时100指数(QDII)人民币A(539003) |